Micrima

Einzelheiten

Land

Großbritannien

Typologie

Eigenkapital

Endtermin

07/08/2025 (267 Tage)

Investoren

184

“Micrima is on a mission to redefine breast cancer screening pathways. The Mi~Scan® technology is being developed as a non-ionising, radiation-free device to improve early detection and personalised risk profiling. Through a breast cancer study using Mi~Scan®, Micrima engages with women in underserved communities.”